Klinik Araştırma Başvurularında Güven Uygulamaları Kılavuzu
SB TITCK 05.06.2024 Tarihli Klinik Araştırma Başvurularında Güven Uygulamaları Kılavuzu hk._EN (003)
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 1of7 TurkishMinistryofHealth TurkishMedicinesandMedicalDevicesAgency GUIDELINEONTHERELIANCEPROCEDUREINCLINICALTRIAL APPLICATIONS KAD-KLVZ-024 InitialVersionEffectiveDate 01.09.2022 1 st RevisionEffectiveDate 05.06.2024
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 2of7 TABLEOFCONTENTS PurposeandBasis.....................................................................................................................3 Scope..........................................................................................................................................3 Basis...........................................................................................................................................3 Definitions.................................................................................................................................3 RecognitionofGoodLaboratoryPracticeCertificatesundertheRelianceProcedure....4 RecognitionofGoodLaboratoryPracticeInspectionReportundertheReliance Procedure..................................................................................................................................4 RecognitionoftheInvestigationalMedicinalProductDossierundertheReliance Procedure..................................................................................................................................5 RecognitionofGoodManufacturingPracticeCertificates/Manufacturing AuthorizationCertificatesundertheRelianceProcedure...................................................5 RecognitionofAuxiliaryMedicinalProductUseundertheRelianceProcedure..............6 Effectiveness..............................................................................................................................6 Enforcement..............................................................................................................................6 References.................................................................................................................................7
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 3of7 PurposeandBasis ARTICLE1–(1)ThisGuidelinesetsforththeprinciplesandproceduresforimplementing therelianceprocedureinevaluatingclinicaltrialapplications. (2)ThisGuidelineisissuedbasedontheRegulationonClinicalTrialsofHumanMedicinal Products,publishedforeffectinOfficialGazette#32203of27.05.2023. Scope ARTICLE2–(1)ThisGuidelinecoverstherecognitionundertherelianceprocedureof decisions/reportsissuedbyotherpharmaceuticalauthoritiesorregional/international organizationswhichimplementcomparablestandardstoourAgencyduringreviewofclinical trials,withoutprejudicetotheentitlementoftheAgencyandtheethicscommitteeconcerned torequireadditionalinformationordocuments. Basis ARTICLE3–(1)ThisGuidelineisissuedbasedontheRegulationonClinicalTrialsof HumanMedicinalProducts,publishedforeffectinOfficialGazette#32203of27.05.2023. Definitions ARTICLE4–(1)ForthepurposesofthisGuideline: a)‘Investigationalmedicinalproduct’meansahumanmedicinalproductwhichistested orusedasreferenceinaclinicaltrial,includingplacebo; b)‘Investigationalmedicinalproductdossier’meansacompilationofdataonthe investigationalmedicinalproduct’squality,andmanufacturingandcontrolprocesses anddatafromitsclinicaluse,includingclinicalandnon-clinicalinvestigations; c)‘ApplicationGuideline’meanstheGuidelineonClinicalTrialApplicationsSubmitted tothePresidencyofClinicalTrialsDepartmentofTurkishMedicinesandMedical DevicesAgency(KAD-KLVZ-02); d)‘Outerpackaging’meansthecontainerinwhichtheimmediatepackageisplaced; e)‘Operatingpermit’meansacertificateofauthorizationgrantedbytheAgencyto investigationalsiteswhereclinicalorbioanalyticalcomponentsofPhaseIclinical trialsorbioavailabilityorbioequivalencestudiesarecarriedout; f)‘Reliance’meanstheAgency,informingadecisiononamatterwithinitsjurisdiction, takingintoaccountorrelyingmainlyonanassessmentorotherreviewthathadbeen conductedbyanotherregulatoryauthorityorcredibleinstitution; g)‘Immediatepackaging’meansacontainerorotherformofpackagingindirectcontact withthehumanmedicinalproduct; h)‘Manufacturing(production)’meansweighing,dispensation,primarypackaging, secondarypackaging,andprocessingtofinishedproductofstartingmaterialsusedin themanufacturingprocessofhumanmedicinalproducts,includinginvestigational medicinalproducts,and/oractivesubstances,includingassociatedcontrolsandbatch releaseoperations;
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 4of7 i)‘Agency’meansTurkishMedicinesandMedicalDevicesAgency; j)‘CompetentAuthority’meanscompetentauthorityfoundingmembersofInternational CouncilforHarmonization(ICH)(theUSFoodandDrugAdministration(USFDA), EuropeanMedicinesAgency(EMA),JapaneseMedicinesandMedicalDevices Agency(PMDA))orcompetentauthoritypermanentmembers(NationalMedicines AuthorityofSwitzerland(Swissmedic)andNationalMedicinesAuthorityofCanada (HealthCanada)),theTherapeuticGoodsAdministrationofAustralia(TGA)andthe MedicinesandHealthcareProductsRegulatoryAgencyoftheUK(MHRA). k)‘Regulation’meanstheRegulationonClinicalTrialsofHumanMedicinalProducts, publishedforeffectinOfficialGazette#32203of27.05.2023. (2)ThedefinitionsoftermsprovidedintheRegulationonClinicalTrialsofHuman MedicinalProducts,theGuidelineonGoodClinicalPracticeandotherapplicableregulations alsoapplytothisGuideline. RecognitionofGoodLaboratoryPracticeCertificatesundertheRelianceProcedure ARTICLE5–(1)Preclinicalpharmacologicalandtoxicologicalstudiesmustbeconducted inlinewiththeguidelinesofGoodLaboratoryPractice(GLP),aspublishedinOfficial Gazette#27516of09.03.2010,andtheRegulationonHarmonizationofTestUnits,Good LaboratoryPracticeandInspectionsofStudies. (2)WheretheGLPconcernedisnotpubliclyavailable,theGLPissuedbytheOrganization forEconomicCooperationandDevelopmentshouldbeprovided. RecognitionofGoodLaboratoryPracticeInspectionReportundertheReliance Procedure ARTICLE6–(1)AsdetailedintheApplicationGuideline,theinvestigationalmedicinal productdossiermustincludeastatementconfirmingthattheclinicaltrialsproposedtothe Agencyareconductedinlinewiththerequirementsofgoodclinicalpractice(GCP). Nevertheless,theAgencymay,atitsdiscretion,requireaninspectionreportissuedbyanother healthauthorityconfirmingthatthestudiesareconductedinlinewithGCP,orconductaGCP inspectionitself. (2)UnlessabreachofTurkishregulationshasbeenidentified,theAgencywillnotconducta GCPinspectionprovidedthataGCPinspectionreportbyaCompetentAuthorityforthe clinicaltrialconcernedhasbeensubmitted,establishingthattheinvestigationalsites/studies inspectedorthedatageneratedinthestudyconcernedareconformanttoGCPrequirements. (3)IftheGCPinspectionreportssubmittedwereissuedbyahealthauthorityotherthana CompetentAuthority,theAgencywillgoaheadwithconductingaGCPinspectionaccording totheapplicableguideline.
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 5of7 RecognitionoftheInvestigationalMedicinalProductDossierundertheReliance Procedure ARTICLE7–(1)TheRegulationrequiressubmissionofaninvestigationalmedicinal productdossier(IMPD)withaclinicaltrialapplication,compiledinlinewiththe requirementsoftheapplicableguidelinesissuedbytheAgency. (2)ForinvestigationalmedicinalproductswhichareauthorizedbyaCompetentAuthoritybut notinTürkiye,itisnotnecessarytosubmitanIMPDiftheinformationprovidingbasisfor marketingauthorizationhasnotbeenmodified;itissufficienttoprovidethenameofthe marketingauthorizationholderandthemarketingauthorizationnumber,withacopyofthe summaryofproductcharacteristicsoranoverviewofproductcharacteristicsorprescribing information. (3)ForinvestigationalmedicinalproductswhichareauthorizedbyaCompetentauthoritybut notinTürkiye,wheretheinformationprovidingbasisformarketingauthorizationhasbeen modified,itissufficienttosubmittherelevantsectionsoftheIMPD,dependingontheextent ofthemodifications,accordingtotheQualityGuidelines.Insuchcase,theAgencywillnot reviewtheIMPDandrecognizeitasvalid,ifthesameIMPDsubmittedtotheAgency,with thesamedateandversionnumber,hadbeenreviewedandapprovedbyaCompetent Authority,asevidencedbyasignedandapostilledcertificate. (4)ForinvestigationalmedicinalproductswhicharenotauthorizedbyaCompetentAuthority norinTürkiye,itisnecessarytosubmitanIMPD.Insuchcase,theAgencywillnotreview theIMPDandrecognizeitasvalid,ifthesameIMPDsubmittedtotheAgency,withthesame dateandversionnumber,hadbeenreviewedandapprovedbyaCompetentAuthority,as evidencedbyasignedandapostilledcertificate. RecognitionofGoodManufacturingPracticeCertificates/Manufacturing AuthorizationCertificatesundertheRelianceProcedure ARTICLE8–(1)Article12oftheRegulationrequiresassurancethattheinvestigational medicinalproductwasmanufacturedinlinewiththerequirementsofgoodmanufacturing practice(GMP). (2)AsspecifiedintheApplicationGuideline,theclinicaltrialapplicationdossiermust includeeitheramanufacturingauthorizationcertificateoraGMPcertificate. a)ItissufficienttosubmitanAgency-recognizeddocumentorinformation,affirming thattheactivesubstance(s)and,whereapplicable,theintermediate(s)usedinthe manufacturingprocessoftheactivesubstance,aremanufacturedinlinewith internationally-recognizedGMP. b)Forallinvestigationalmedicinalproductstobeusedintheclinicaltrial,the applicationdossiermustincludebatchreleasecertificate(s),batchanalysis/quality controlcertificate(s),andGMPcertificate(s)forthemanufacturingsite(s)whereall manufacturingsteps,exceptouterpackagingandlabeling,areperformed. 1)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteholdingamanufacturingauthorizationcertifiedissuedby theAgency,Annex2totheManufacturingAuthorizationCertificate(activities involvinginvestigationalhumanmedicinalproducts)mustbeavailableforthe investigationalmedicinalproducts;Annex2totheManufacturing AuthorizationCertificatemustcoverallrequisitemanufacturingstepsofthe investigationalmedicinalproduct.
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 6of7 2)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteabroad,asignedandapostilledGMPcertificate,issuedbya competentauthoritypartytoPIC/SandaICH,mustbesubmitted.Wherethe competentauthorityconcerneddoesnotpubliclyrevealinformationabout facilities,areferencenumber/details/certificates(e.g.EudraGMPextract), foraccessingthisinformation,mustbeprovided. 3)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteabroadandtheGMPcertificatewasissuedbyaauthority otherthanonewhoispartytoPIC/SorICH,asignedandapostilledletterof approvalissuedfortheproposedclinicaltrialbyaCompetentAuthoritymust beprovided,withaformalaffirmationthattheinvestigationalmedicinal producttobeusedintheclinicaltrialinTürkiyeismanufacturedatthesame manufacturingsiteastheonetobeusedinthecountryoftheapproving CompetentAuthority. 4)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteabroadandtheGMPcertificatesubmittedforthe manufacturingsitewasnotissuedbyacompetentauthoritypartytoPIC/Sor ICH,andthedocumentslistedunderPoint3abovecannotbesubmitted,the AgencywillconductaGMPinspection. c)ItissufficienttosubmitanAgency-recognizedcertificateorinformation,showing conformitytointernationally-recognizedGMPrequirements,forfacilitiesresponsible forbatchrelease,batchanalysis/qualitycontrol,outerpackagingandlabeling operations. RecognitionofAuxiliaryMedicinalProductUseundertheRelianceProcedure ARTICLE9–(1)AccordingtotheRegulation,auxiliarymedicinalproductsmustbe authorizedinTürkiye. (2)Ifjustifiedbytheapplicant,however,theAgencymayacceptuseofhumanmedicinal products,whichareauthorizedbyaCompetentAuthorityandusedinlinewiththeproduct informationprovidingbasisformarketingauthorization,asanauxiliarymedicinalproduct. (3)TheprovisionsmadeinArticles7and8ofthisGuidelinealsoapplytoauxiliarymedicinal products. Effectiveness ARTICLE10–(1)ThisGuidelinewillbecomeeffectiveafterapprovalbytheAgency President. Enforcement ARTICLE11–(1)TheAgencyPresidentwillenforcethisGuideline.
DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 7of7 References 1.RegulationonManufacturingFacilitiesofHumanMedicinalProducts,publishedin OfficialGazette#30217of21.10.2017. 2.RegulationonMarketingAuthorizationofHumanMedicinalProducts,publishedin OfficialGazette#31686of11.12.2021. 3.RegulationonClinicalTrialsofHumanMedicinalProducts,publishedinOfficialGazette #31686of27.05.2023. 4.GuidelineonChemicalandPharmaceuticalQualityRequirementsforHumanMedicinal ProductsUsedinClinicalTrials 5.GuidelineonQualityRequirementsforBiologicalMedicinalProductsUsedinClinical Trials 6.GuidelineonClinicalTrialApplicationsSubmittedtothePresidencyofClinicalTrials DepartmentofTurkishMedicinesandMedicalDevicesAgency REVISIONHISTORY RevisionNumber RevisionDate RationaleandDescription 01 UpdatedArticles6and8toalignwiththe newRegulation. UpdatedArticles7and9toalignwiththe newRegulation. Reviewedandupdatedtoalignwiththe newRegulation.